Citeline药品研发年度回顾2015.pdfVIP

citeline Pharma rd annual review 2015 1 Welcome to Citeline’s 2015 review of trends in pharmaceutical RD. For around a quarter of a century now, I’ve been taking an annual look at the state of the pharma RD universe, and comparing it to similar data gathered over the many years during which Pharmaprojects has led the way in gathering global pharma RD intelligence. By looking at our information on commercial pipelines over several years, I’ve identified new trends, raised alarm bells at worrisome signs, observed the brightest star drugs in the industry succeed, and watched some drug development strategies collapse into black holes. In this article, we will be seeing how the pipeline has changed in the past twelve months, and will be looking for pointers as to what the new year might bring. Here, we’ll be concentrating on the pipeline as a whole. I’ll be adding my thoughts as to the industry’s success stories of the year just passed when we issue our review of 2014’s New Active Substance launches as a supplement to this report, at the beginning of March 2015. This analysis, however, slices and dices pharma RD as we report it in mid-January 2015. 2 total pipeline size – a stellar expansion As usual, we start with the keenly-anticipated headline figure, Citeline’s annual count of the total number of drugs in the development pipeline. This year, the news is again stellar: the figure’s up to 12,300. This is another sizeable year-on-year increase, a rise of 8.8%, exceeding even the 7.9% reported in 2014. In terms of actual numbers of RD projects, at 993, considerably more have been added to the total through 2014 than the 828 extra from 2013. So it would seem that pipeline expansion is continuing and even gaining pace – along, presumably, with the inevitable concomitan